Clovis Oncology Sells Cancer Drug Rubraca to Swiss Pharma

Rubraca to be acquired by privately held pharma Schweiz GmbH

Deal finalized as Clovis Oncology files for bankruptcy protection

Clovis Oncology Inc. (CLVS) has announced the sale of its approved cancer drug Rubraca to pharma Schweiz GmbH, a privately held Austrian company. The sale comes as Clovis Oncology has filed for bankruptcy protection in Delaware.

Rubraca, a treatment for certain types of ovarian cancer, prostate cancer, and breast cancer, is now owned by pharma Schweiz GmbH. The company has advised that for questions outside of adverse events, inquiries should be directed to pharma Schweiz GmbH.

The sale of Rubraca marks a significant development for Clovis Oncology, which has been struggling financially in recent years. The company's shares have plummeted in value, and it has been facing pressure from creditors. The bankruptcy filing will allow Clovis Oncology to restructure its debts and continue operating